Literature DB >> 33035651

Inpatient Specialty-Level Palliative Care Is Delivered Late in the Course of Hepatocellular Carcinoma and Associated With Lower Hazard of Hospital Readmission.

Christopher D Woodrell1, Nathan E Goldstein2, Jaison R Moreno3, Thomas D Schiano4, Myron E Schwartz5, Melissa M Garrido6.   

Abstract

CONTEXT: Little is known about receipt of specialty-level palliative care by people with hepatocellular carcinoma (HCC) or its impact on health care utilization.
OBJECTIVES: Identify patient characteristics associated with receipt of specialty-level palliative care among hospitalized HCC patients and measure association with time to readmission.
METHODS: We used logistic regression to examine relationships between receipt of inpatient palliative care consultation by HCC patients at an academic center (N = 811; 2012-2016) and clinical and demographic covariates at index hospitalization. We used a survival analysis model accounting for competing risk of mortality to compare time to readmission among individuals who did or did not receive palliative care during the admission and performed a sensitivity analysis using kernel weights to account for selection bias.
RESULTS: Overall, 16% received inpatient palliative care consults. Those who received consults had worse laboratory values than those who did not. In a multivariable model, higher Model for End-Stage Liver Disease Sodium, receipt of sorafenib, and higher pain scores were significantly associated with increased odds of palliative care, whereas liver transplantation and admission to a surgical service were associated with lower odds. For time to readmission (2076 hospitalizations for 811 individuals with 175 palliative care visits), the subhazard ratio for readmission for patients who received consults was 0.26 (95% CI = 0.18-0.38) and 0.35 (95% CI = 0.24-0.52) with a kernel-weighted sample.
CONCLUSION: Inpatient palliative care consultation was received by individuals with more advanced disease and associated with lower readmission hazard. These findings support further research and the development of HCC-specific programs that increase access to specialty-level palliative care. Published by Elsevier Inc.

Entities:  

Keywords:  Palliative care; end-stage liver disease; hepatocellular carcinoma; hospital readmission; supportive oncology

Mesh:

Year:  2020        PMID: 33035651      PMCID: PMC8021616          DOI: 10.1016/j.jpainsymman.2020.09.040

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  39 in total

Review 1.  Molecular therapies and precision medicine for hepatocellular carcinoma.

Authors:  Josep M Llovet; Robert Montal; Daniela Sia; Richard S Finn
Journal:  Nat Rev Clin Oncol       Date:  2018-10       Impact factor: 66.675

2.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 3.  Economic impact of hospital inpatient palliative care consultation: review of current evidence and directions for future research.

Authors:  Peter May; Charles Normand; R Sean Morrison
Journal:  J Palliat Med       Date:  2014-07-01       Impact factor: 2.947

4.  Methods for constructing and assessing propensity scores.

Authors:  Melissa M Garrido; Amy S Kelley; Julia Paris; Katherine Roza; Diane E Meier; R Sean Morrison; Melissa D Aldridge
Journal:  Health Serv Res       Date:  2014-04-30       Impact factor: 3.402

5.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

6.  Symptom Distress in Patients With Hepatocellular Carcinoma Toward the End of Life.

Authors:  Lissi Hansen; Nathan F Dieckmann; Kenneth J Kolbeck; Willscott E Naugler; Michael F Chang
Journal:  Oncol Nurs Forum       Date:  2017-11-01       Impact factor: 2.172

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

8.  Health Care Utilization and End-of-Life Care Outcomes for Patients With Decompensated Cirrhosis Based on Transplant Candidacy.

Authors:  Nneka N Ufere; Jennifer L Halford; Joshua Caldwell; Min Young Jang; Sunil Bhatt; John Donlan; Janet Ho; Vicki Jackson; Raymond T Chung; Areej El-Jawahri
Journal:  J Pain Symptom Manage       Date:  2019-10-23       Impact factor: 3.612

9.  The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.

Authors:  Xu-Dong Qu; Cheng-Shi Chen; Jian-Hua Wang; Zhi-ping Yan; Jie-min Chen; Gao-quan Gong; Qin-xin Liu; Jian-jun Luo; Lin-xiao Liu; Rong Liu; Sheng Qian
Journal:  BMC Cancer       Date:  2012-06-21       Impact factor: 4.430

10.  Does palliative care improve quality? A survey of bereaved family members.

Authors:  Laura P Gelfman; Diane E Meier; R Sean Morrison
Journal:  J Pain Symptom Manage       Date:  2008-04-14       Impact factor: 3.612

View more
  1 in total

Review 1.  Palliative care models for patients living with advanced cancer: a narrative review for the emergency department clinician.

Authors:  Corita R Grudzen; Paige C Barker; Jason J Bischof; Allison M Cuthel; Eric D Isaacs; Lauren T Southerland; Rebecca L Yamarik
Journal:  Emerg Cancer Care       Date:  2022-08-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.